Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-cjp7w Total loading time: 0 Render date: 2024-07-04T01:50:53.022Z Has data issue: false hasContentIssue false

Chapter 30 - Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease

from Section IV - Clinical Trials in Parkinson's Diease: Lessons, Controversies and Challenges

Published online by Cambridge University Press:  05 March 2016

By
Daniel Weintraub  and
Lama M. Chahine
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 325 - 336
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Emre, M, Aarsland, D, Brown, R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689–707; quiz 1837.CrossRefGoogle ScholarPubMed
Kehagia, AA, Barker, RA, Robbins, TW. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis 2013; 11: 79–92.Google Scholar
Emre, M, Aarsland, D, Albanese, A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509–18.Google Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Arlington, VA: American Psychiatric Publishing, 2013.Google Scholar
Olin, JT, Aarsland, D, Meng, X. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dement Geriatr Cogn Disord 2010; 29: 510–15.CrossRefGoogle ScholarPubMed
Seppi, K, Weintraub, D, Coelho, M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl. 3): S42–80.Google Scholar
Leroi, I, Brandt, J, Reich, SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004; 19: 1–8.Google Scholar
Ravina, B, Putt, M, Siderowf, A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934–9.Google Scholar
Aarsland, D, Laake, K, Larsen, JP, Janvin, C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708–12.CrossRefGoogle ScholarPubMed
Dubois, B, Tolosa, E, Katzenschlager, R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012; 27: 1230–8.CrossRefGoogle ScholarPubMed
Lipton, SA, Rosenberg, PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613–22.Google ScholarPubMed
McShane, R, Areosa Sastre, A, Minakaran, N. Memantine for dementia. Cochrane Database Syst Rev 2006; (2): CD003154.Google Scholar
Leroi, I, Overshott, R, Byrne, EJ, Daniel, E, Burns, A. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009; 24: 1217–21.CrossRefGoogle ScholarPubMed
Emre, M, Tsolaki, M, Bonuccelli, U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969–77.CrossRefGoogle ScholarPubMed
Weintraub, D, Mavandadi, S, Mamikonyan, E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010; 75: 448–55.Google Scholar
Trillo, L, Das, D, Hsieh, W, et al. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care. Neurosci Biobehav Rev 2013; 37: 1363–79.CrossRefGoogle ScholarPubMed
Del Tredici, K, Braak, H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J Neurol Neurosurg Psychiatry 2013; 84: 774–83.CrossRefGoogle ScholarPubMed
Pedersen, KF, Larsen, JP, Tysnes, OB, Alves, G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013; 70: 580–6.Google Scholar
Hanagasi, HA, Gurvit, H, Unsalan, P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011; 26: 1851–8.Google Scholar
US National Institutes of Health. Parallel-group study to assess the effect of rasagiline on cognition in patients with Parkinson's disease. Available at: http://clinicaltrials.gov/show/NCT01723228.Google Scholar
Marsh, L, Biglan, K, Gerstenhaber, M, Williams, JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009; 24: 277–82.Google Scholar
Sammer, G, Reuter, I, Hullmann, K, Kaps, M, Vaitl, D. Training of executive functions in Parkinson's disease. J Neurol Sci 2006; 248: 115–19.CrossRefGoogle ScholarPubMed
Edwards, JD, Hauser, RA, O'Connor, ML, et al. Randomized trial of cognitive speed of processing training in Parkinson disease. Neurology 2013; 81: 1284–90.Google Scholar
Marsh, L, McDonald, WM, Cummings, J, Ravina, B, NINDS/NIMH Work Group on Depression and Parkinson's Disease. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148–58.Google Scholar
Weintraub, D, Morales, KH, Moberg, PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005; 20: 1161–9.Google Scholar
Richard, IH, McDermott, MP, Kurlan, R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78: 1229–36.Google Scholar
Menza, M, Dobkin, RD, Marin, H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886–92.CrossRefGoogle ScholarPubMed
Devos, D, Dujardin, K, Poirot, I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008; 23: 850–7.Google Scholar
Barone, P, Poewe, W, Albrecht, S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573–80.Google Scholar
Barone, P, Scarzella, L, Marconi, R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253: 601–7.Google Scholar
Pahwa, R, Stacy, MA, Factor, SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108–15.Google Scholar
Rascol, O, Brooks, DJ, Melamed, E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947–54.Google Scholar
Korchounov, A, Winter, Y, Rossy, W. Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin Neuropharmacol 2012; 35: 121–4.Google Scholar
Olanow, CW, Rascol, O, Hauser, R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268–78.Google Scholar
Dobkin, RD, Menza, M, Allen, LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011; 168: 1066–74.CrossRefGoogle ScholarPubMed
Follett, KA, Weaver, FM, Stern, M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362: 2077–91.Google Scholar
Forsaa, EB, Larsen, JP, Wentzel-Larsen, T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67: 996–1001.CrossRefGoogle ScholarPubMed
Ravina, B, Marder, K, Fernandez, HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22: 1061–8.CrossRefGoogle ScholarPubMed
Fenelon, G, Alves, G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010; 289: 12–17.Google Scholar
Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757–63.CrossRefGoogle Scholar
Weintraub, D, Chen, P, Ignacio, RV, Mamikonyan, E, Kales, HC. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 2011; 68: 899–904.Google Scholar
Friedman, JH, Berman, RM, Goetz, CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006; 21: 2078–81.CrossRefGoogle ScholarPubMed
Marras, C, Gruneir, A, Wang, X, et al. Antipsychotics and mortality in parkinsonism. Am J Geriatr Psychiatry 2012; 20: 149–58.Google Scholar
Cummings, J, Isaacson, S, Mills, R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2013; 383: 533–40.CrossRefGoogle ScholarPubMed
Weintraub, D, Koester, J, Potenza, MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.CrossRefGoogle ScholarPubMed
Weintraub, D, Papay, K, Siderowf, A, Parkinson's Progression Markers Initiative. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case–control study. Neurology 2013; 80: 176–80.Google Scholar
Okai, D, Askey-Jones, S, Samuel, M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 2013; 80: 792–9.Google Scholar
Troeung, L, Egan, SJ, Gasson, N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. PLoS One 2013; 8: e79510.Google Scholar
Devos, D, Moreau, C, Maltete, D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2013; 85: 668–74.Google Scholar
Thobois, S, Lhommee, E, Klinger, H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 136: 1568–77.CrossRefGoogle ScholarPubMed
Friedman, JH, Ravina, B, Mills, R. A multicenter, placebo controlled, double blind trial to examine the safety and efficacy of pimavanserin in the treatment of psychosis in Parkinson's disease. Neurology 2010; 74: A299.Google Scholar
Walsh, BT, Seidman, SN, Sysko, R, Gould, M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840–7.CrossRefGoogle ScholarPubMed
Goetz, CG, Wuu, J, McDermott, MP, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008; 23: 690–9.Google Scholar
Aarsland, D, Ballard, C, Walker, Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613–18.Google Scholar
Michael J. Fox Foundation. Fox Trial Finder. Available at: https://foxtrialfinder.michaeljfox.org/.Google Scholar
Starkstein, SE, Dragovic, M, Dujardin, K, et al. Anxiety has specific syndromal profiles in Parkinson disease: a data-driven approach. Am J Geriatr Psychiatry 2013; 22: 1410–17.CrossRefGoogle Scholar
Dubois, B, Burn, D, Goetz, C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society task force. Mov Disord 2007; 22: 2314–24.Google Scholar
Litvan, I, Aarsland, D, Adler, CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011; 26: 1814–24.Google Scholar
Robert, P, Onyike, CU, Leentjens, AF, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009; 24: 98–104.Google Scholar
Drijgers, RL, Dujardin, K, Reijnders, JS, Defebvre, L, Leentjens, AF. Validation of diagnostic criteria for apathy in Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 656–60.Google Scholar
Weintraub, D, Mamikonyan, E, Papay, K, et al. Questionnaire for impulsive-compulsive disorders in Parkinson's disease – rating scale. Mov Disord 2012; 27: 242–7.Google Scholar
Giovannoni, G, O'sullivan, JD, Turner, K, Manson, AJ, Lees, AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423–8.CrossRefGoogle ScholarPubMed
Barton, B, Grabli, D, Bernard, B, et al. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord 2012; 27: 248–53.Google Scholar
Schrag, A, Barone, P, Brown, RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007; 22: 1077–92.Google Scholar
Fernandez, HH, Aarsland, D, Fenelon, G, et al. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord 2008; 23: 484–500.Google Scholar
Leentjens, AF, Dujardin, K, Marsh, L, et al. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008; 23: 2004–14.Google Scholar
Leentjens, AF, Dujardin, K, Marsh, L, et al. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008; 23: 2015–25.Google Scholar
Voss, T, Bahr, D, Cummings, J, et al. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. Parkinsonism Relat Disord 2013; 19: 295–9.CrossRefGoogle ScholarPubMed
Martinez-Martin, P, Rojo-Abuin, JM, Dujardin, K, et al. Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis. Eur J Neurol 2013; 20: 1198–203.Google Scholar
Schneider, LS, Tariot, PN, Dagerman, KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525–38.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×